Angstrom Pharmaceuticals, Inc.
Records under this name other than patents Angstrom Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Angstrom Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,697,629 | Modulation of intracellular signaling Lapsed on the fee record Ended Apr 15, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 15, 2026 | From the USPTO record |
| US 8,313,914 | Compositions and methods for modulation of cell migration Lapsed on the fee record Ended Nov 20, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 20, 2024 | From the USPTO record |
| US 7,807,621 | Anti-invasive and anti-angiogenic compositions Lapsed on the fee record Ended Oct 5, 2018 · From the USPTO record | Lapsed on the fee record | Ended Oct 5, 2018 | From the USPTO record |
| US 6,696,416 | Anti-invasive and anti-angiogenic compositions Term ended Term ended Jul 25, 2017 · From the USPTO record | Term ended | Term ended Jul 25, 2017 | From the USPTO record |
| US 6,936,587 | Anti-invasive and anti-angiogenic compositions Term ended Ended no later than Jul 25, 2017 · From the USPTO record | Term ended | Ended no later than Jul 25, 2017 | From the USPTO record |
| US 8,110,543 | Anti-invasive and anti-angiogenic compositions Term ended Term ended Jul 25, 2017 · From the USPTO record | Term ended | Term ended Jul 25, 2017 | From the USPTO record |
| US 6,514,710 | Method of using cyclic peptides to inhibit binding to urokinase-type plasminogen activator receptor Lapsed on the fee record Ended Feb 4, 2015 · From the USPTO record | Lapsed on the fee record | Ended Feb 4, 2015 | From the USPTO record |
| US 6,277,818 | Cyclic peptide ligands that target urokinase plasminogen activator receptor Lapsed on the fee record Ended Aug 21, 2013 · From the USPTO record | Lapsed on the fee record | Ended Aug 21, 2013 | From the USPTO record |
| US 6,896,870 | Diagnostic probes and therapeutics targeting uPA and uPAR Lapsed on the fee record Ended May 24, 2013 · From the USPTO record | Lapsed on the fee record | Ended May 24, 2013 | From the USPTO record |
| US 5,942,492 | Cyclic peptides that bind to urokinase-type plasminogen activator receptor Term ended Term ended no later than Aug 24, 2019 · Low confidence | Term ended | Term ended no later than Aug 24, 2019 | Low confidence |